U.S. Latent Tuberculosis Infection Detection Market (2026 – 2033) Size, Share & Trends Analysis Report By Test (IGRA, TST), By Application (Household Contacts With Pulmonary TB, PLHIV), By End-use (Diagnostic Laboratories, Hospitals/Clinics), By Region, And Segment Forecasts

Comparison of LTBI diagnostic methods in the U.S. 

Parameter	Tuberculin Skin Test (TST)	Interferon-Gamma Release Assay (IGRA)
Test Type	Intradermal skin test	Blood-based laboratory test
Patient Visits Required	Two (administration + reading)	One visit (blood draw)
Result Interpretation	Subjective measurement of induration	Objective laboratory measurement
Impact of BCG Vaccination	May cause false positives	No cross-reactivity
Sensitivity in Immunocompromised Patients	Reduced	Moderately improved vs TST
Turnaround Time	48-72 hours	~24 hours (lab dependent)
Infrastructure Needs	Minimal	CLIA-certified lab & instrumentation
Cost	Low	Higher than TST
Use Settings	Public health, clinics, occupational screening	Hospitals, reference labs, targeted screening
Key Advantage	Low cost & accessibility	Higher specificity & single-visit workflow

How has COVID19 impacted this market? To know more request a free sample copy Source: National Society of Tuberculosis Clinicians, Testing and Treatment of Latent Tuberculosis Infection in the U.S.: Clinical Recommendations, 2024 Moreover, the growing focus on tuberculosis (TB) elimination and preventive care is creating a strong market growth opportunity for the U.S. Public health authorities increasingly recognize that most active TB cases in the U.S. result from reactivation of latent infection rather than recent transmission. As a result, national TB elimination strategies have shifted toward identifying and treating LTBI before it progresses to active disease, placing greater emphasis on early and accurate diagnostic testing. This preventive focus is reflected in updated screening guidelines and targeted testing initiatives. For instance, the Centers for Disease Control and Prevention (CDC) and the U.S. Preventive Services Task Force (USPSTF) recommend LTBI screening for individuals at increased risk, including immigrants from high TB-burden countries, healthcare workers, people living with HIV, and patients receiving immunosuppressive therapies such as TNF-alpha inhibitors. These recommendations have driven routine LTBI testing in primary care, occupational health, and specialty clinics, directly increasing demand for latent TB diagnostic tests across healthcare settings.

LTBI Testing Decision Flow

However, limited awareness and the resulting underdiagnosis of latent tuberculosis infection (LTBI) represent a significant restraint on the U.S. LTBI detection market. Unlike active TB, latent TB is asymptomatic and does not cause immediate illness, which leads many individuals to underestimate the importance of screening. As a result, testing is often pursued only when required for employment, immigration, or specific medical conditions, rather than as a routine preventive measure. This low level of public awareness reduces voluntary testing rates and limits the overall demand for LTBI diagnostic services.

Market Concentration & Characteristics

The degree of innovation in the U.S. latent tuberculosis infection (LTBI) detection market is moderate and has accelerated in response to the need for faster, more scalable, and highly accurate detection to support TB elimination goals. Molecular diagnostics, interferon-gamma release assays (IGRAs), and next-generation sequencing (NGS) are increasingly shaping the future of LTBI detection. These innovations support earlier identification, better surveillance, and more informed clinical decision-making. Mergers and acquisitions in the LTBI detection market have increasingly been focused on expanding laboratory networks, strengthening specialty testing capabilities, and improving access to high-quality screening services. Strategic transactions are enabling major laboratory service providers to broaden their reach, integrate advanced testing platforms, and enhance service delivery for TB screening programs across hospital systems, public health departments, and employer-based screening initiatives. Regulatory oversight plays a critical role in shaping the adoption of LTBI diagnostics in the United States. FDA clearance requirements ensure high standards of clinical performance, reliability, and reproducibility for TB diagnostic assays and automated platforms. In parallel, guidance from the Centers for Disease Control and Prevention (CDC) and the U.S. Preventive Services Task Force (USPSTF) supports targeted LTBI screening among high-risk populations, influencing testing volumes and reimbursement coverage. Diagnostic manufacturers continue to expand TB testing portfolios through enhanced IGRA assays, automation solutions, and workflow optimization tools designed to improve throughput and turnaround time. Product enhancements emphasize improved sensitivity, simplified laboratory workflows, and compatibility with automated liquid handling and laboratory information systems.

Report Coverage & Deliverables

Test Insights

Tuberculin skin test (TST) dominated the market and accounted for the largest revenue share of 67.48% in 2025. The dominance of the segment is attributed to its widespread use as a reliable and cost-effective method for screening latent tuberculosis infection (LTBI). The test involves intradermal injection of tuberculin purified protein derivative (PPD) into the inner surface of the skin using the Mantoux method, after which the injection site is evaluated 48-72 hours later for induration. In individuals with no known risk factors, an induration of 15 mm or greater is typically considered positive. The TST remains highly penetrated across public health programs, occupational screening, and routine clinical practice due to its affordability, established clinical acceptance, and ease of deployment. Interferon Gamma Released Assay (IGRA) is projected to experience the fastest CAGR of 6.39% during the forecast period. This growth is driven by the increasing adoption of blood-based testing for latent tuberculosis infection (LTBI), supported by its clinical and operational advantages over the tuberculin skin test (TST). IGRAs detect infection by measuring interferon-gamma released by sensitized T cells in response to TB-specific antigens, enabling objective, laboratory-based interpretation. In the U.S., these tests are favored because they require only a single patient visit for blood collection, improving compliance in outpatient care, occupational health screening, and public health contact investigations where follow-up visits can be challenging.

Application Insights

People living with HIV (PLHIV) segment accounted for the largest market share of 42.85% in 2025, attributed to their substantially elevated risk of progression from latent infection to active TB disease. HIV infection is recognized by the CDC as one of the strongest risk factors for TB activation, and U.S. clinical guidelines recommend routine TB screening as part of comprehensive HIV care. Even in low-incidence settings, TB remains an important opportunistic infection among PLHIV, particularly in individuals with additional risk factors such as foreign birth or immunosuppressive therapy. Both the tuberculin skin test (TST) and interferon-gamma release assays (IGRAs) are used for LTBI screening; however, immune suppression may reduce test sensitivity. For PLHIV, a TST induration of ≥5 mm is considered positive. IGRAs are often preferred in HIV care settings due to higher specificity and operational convenience. Ongoing risk-based screening and integration of LTBI management into HIV programs continue to sustain testing demand in this high-risk population. Household contacts with pulmonary TB is likely to grow at the fastest CAGR of 6.19% over the forecast period. In the U.S., household contacts of individuals with infectious pulmonary tuberculosis represent one of the highest-priority populations for TB contact investigations and latent tuberculosis infection (LTBI) screening. Close and prolonged exposure significantly increases the risk of TB transmission, and U.S. public health authorities consistently prioritize this group for early identification and preventive treatment. According to the U.S. Centers for Disease Control and Prevention (CDC), targeted testing of close contacts is a cornerstone of TB control efforts, as untreated LTBI in this population carries a measurable risk of progression to active disease, particularly within the first two years following exposure.

End Use Insights

Diagnostic laboratories led the LTBI detection market, accounting for 54.55% of the revenue share in 2025, owing to efforts to improve patient outcomes by providing diagnostic facilities at the retail level. Moreover, the ability of laboratories to handle a large volume of tests at an expedited rate is expected to further fuel the segment over the forecast period. Furthermore, diagnostic laboratories also deal with samples received from clinics and hospitals. Diagnostic laboratories are providing newer blood tests for the screening or detection of LTBIs. For instance, independent laboratories such as Dynacare and Life Labs provide tests, such as QuantiFERON-TB blood tests and T-SPOT.TB tests, for the detection of LTBI, are available at comparatively lower prices. In addition, in March 2023, the U.S. Food and Drug Administration approved two additional cell isolation instruments from PerkinElmer’s Oxford Immunotec for use with the T-Cell Select™ reagent kit, aiding in the diagnosis of tuberculosis (TB) in vitro. This approval enhances the automation of TB detection, reducing time and labor for laboratories and providing faster and more reliable results for patients. The hospitals/clinics segment is expected to grow at a lucrative rate over the forecast period. Individuals with medical conditions, such as HIV/AIDS, chronic renal failure, and other diseases that weaken the immune system, are at increased risk of LTBI and its development into an active TB case. The increasing prevalence of diseases that affect the immune system is likely to boost the testing rate for LTBIs in hospitals and clinics. The penetration of TST is higher in hospitals and clinics, as it requires standardization of procedures and trained professionals to conduct tests & read the skin test reaction. Moreover, TST does not require specific equipment and reagent kits to detect latent tuberculosis infection. In addition, LTBI detection market players, such as bioMérieux, are working to equip hospital laboratories with the newer blood test for the detection of LTBI.

Key U.S. Latent Tuberculosis Infection Detection Company Insights

The competitive scenario in the LTBI detection market is high, with key players such as QIAGEN, Euroimmun US, bioMérieux, and Oxford Immunotec holding significant positions. Prominent market participants are focusing on increasing their customer base using acquisition strategies.

Recent Developments

• In April 2025, Revvity announced the U.S. FDA approval of the Auto-Pure 2400 liquid handling platform with the T-SPOT.TB test. The product was initially introduced outside the U.S. in 2024. This integrated solution enables laboratories to enhance productivity while maintaining high clinical performance in latent tuberculosis (TB) detection. The approval represents an advancement in TB control, offering a faster, high-throughput testing solution that delivers accurate results to support timely treatment and disease containment in the U.S.
• In March 2025, BioReference/OPKO Health entered into an agreement for Labcorp to acquire selected assets of BioReference’s clinical testing businesses, expanding clinical laboratory access and service footprint. As part of the agreement, Labcorp will take over BioReference Health’s U.S.-based oncology and oncology-related laboratory testing operations, along with associated customer relationships and select operational assets.
• In January 2025, SD Biosensor’s latent TB diagnostic product STANDARD E TB-Feron ELISA was officially included in the WHO’s list of recommended TB diagnostics following a Pathway B evaluation, affirming performance comparable to existing WHO-recommended tests.

U.S. Latent Tuberculosis Infection Detection Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. latent tuberculosis infection detection market report based on test, application, and end use:

• Test Outlook (Revenue, USD Million, 2021 - 2033) (Volume, Number of Tests in Thousands)
  • Interferon Gamma Released Assay (IGRA)
    • QFT
    • T.SPOT
  • Tuberculin Skin Test (TST)
• Application Outlook (Revenue, USD Million, 2021 - 2033) (Volume, Number of Tests in Thousands)
  • Household Contacts With Pulmonary TB
  • PLHIV
  • Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033) (Volume, Number of Tests in Thousands)
  • Diagnostic Laboratories
  • Hospitals/Clinics
  • Academic & Research Institutions